C WorldWide Group Holding A S raised its position in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 535.8% in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 38,146 shares of the pharmaceutical company’s stock after buying an additional 32,146 shares during the period. C WorldWide Group Holding A S’s holdings in Vertex Pharmaceuticals were worth $5,800,000 at the end of the most recent reporting period.
A number of other institutional investors and hedge funds have also recently made changes to their positions in VRTX. Jennison Associates LLC boosted its position in Vertex Pharmaceuticals by 253.8% during the 2nd quarter. Jennison Associates LLC now owns 5,055,122 shares of the pharmaceutical company’s stock valued at $651,454,000 after buying an additional 3,626,368 shares during the period. Old Mutual Global Investors UK Ltd. boosted its position in Vertex Pharmaceuticals by 1,384.7% during the 2nd quarter. Old Mutual Global Investors UK Ltd. now owns 1,195,455 shares of the pharmaceutical company’s stock valued at $154,058,000 after buying an additional 1,114,939 shares during the period. Assenagon Asset Management S.A. boosted its position in Vertex Pharmaceuticals by 9,422.3% during the 3rd quarter. Assenagon Asset Management S.A. now owns 893,380 shares of the pharmaceutical company’s stock valued at $135,829,000 after buying an additional 883,998 shares during the period. AJO LP purchased a new stake in Vertex Pharmaceuticals during the 2nd quarter valued at $71,956,000. Finally, Vanguard Group Inc. boosted its position in Vertex Pharmaceuticals by 3.1% during the 2nd quarter. Vanguard Group Inc. now owns 16,979,872 shares of the pharmaceutical company’s stock valued at $2,188,196,000 after buying an additional 504,982 shares during the period. 93.06% of the stock is owned by institutional investors and hedge funds.
In other news, COO Ian F. Smith sold 2,155 shares of Vertex Pharmaceuticals stock in a transaction that occurred on Friday, November 3rd. The shares were sold at an average price of $150.00, for a total value of $323,250.00. Following the completion of the sale, the chief operating officer now directly owns 43,043 shares in the company, valued at $6,456,450. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Amit Sachdev sold 40,000 shares of Vertex Pharmaceuticals stock in a transaction that occurred on Tuesday, October 31st. The stock was sold at an average price of $145.05, for a total transaction of $5,802,000.00. Following the completion of the sale, the executive vice president now owns 89,810 shares of the company’s stock, valued at $13,026,940.50. The disclosure for this sale can be found here. Insiders sold 220,094 shares of company stock valued at $32,074,719 over the last quarter. Company insiders own 1.80% of the company’s stock.
WARNING: “C WorldWide Group Holding A S Has $5.80 Million Holdings in Vertex Pharmaceuticals Incorporated (VRTX)” was first reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this piece of content on another publication, it was illegally stolen and reposted in violation of United States & international trademark and copyright laws. The legal version of this piece of content can be viewed at https://www.dispatchtribunal.com/2017/11/12/c-worldwide-group-holding-a-s-has-5-80-million-holdings-in-vertex-pharmaceuticals-incorporated-vrtx.html.
Shares of Vertex Pharmaceuticals Incorporated (VRTX) traded up $0.57 during mid-day trading on Friday, hitting $148.74. 861,000 shares of the stock were exchanged, compared to its average volume of 1,793,065. Vertex Pharmaceuticals Incorporated has a 52-week low of $71.46 and a 52-week high of $167.85. The company has a market capitalization of $37,616.79, a price-to-earnings ratio of 247.90, a PEG ratio of 3.78 and a beta of 1.63. The company has a debt-to-equity ratio of 0.01, a current ratio of 3.28 and a quick ratio of 3.14.
Vertex Pharmaceuticals (NASDAQ:VRTX) last announced its quarterly earnings results on Wednesday, October 25th. The pharmaceutical company reported $0.53 EPS for the quarter, topping analysts’ consensus estimates of $0.04 by $0.49. Vertex Pharmaceuticals had a net margin of 8.53% and a return on equity of 9.23%. The firm had revenue of $578.20 million during the quarter, compared to analyst estimates of $522.07 million. During the same period in the previous year, the business posted $0.16 earnings per share. The business’s revenue for the quarter was up 39.7% on a year-over-year basis. sell-side analysts forecast that Vertex Pharmaceuticals Incorporated will post 0.72 EPS for the current year.
VRTX has been the subject of several analyst reports. Cowen and Company reissued a “buy” rating on shares of Vertex Pharmaceuticals in a research report on Tuesday, August 1st. Zacks Investment Research cut shares of Vertex Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, October 24th. Credit Suisse Group raised their target price on shares of Vertex Pharmaceuticals from $125.00 to $195.00 and gave the stock an “outperform” rating in a research report on Wednesday, July 19th. DA Davidson started coverage on shares of Vertex Pharmaceuticals in a research report on Friday, September 29th. They issued a “buy” rating and a $200.00 target price for the company. Finally, Jefferies Group LLC reaffirmed a “buy” rating on shares of Vertex Pharmaceuticals in a research report on Tuesday, August 22nd. One analyst has rated the stock with a sell rating, five have given a hold rating and twenty-three have given a buy rating to the stock. The company currently has an average rating of “Buy” and an average target price of $173.15.
Vertex Pharmaceuticals Company Profile
Vertex Pharmaceuticals Incorporated is engaged in discovering, developing, manufacturing and commercializing medicines for serious diseases. The Company is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs in other indications.
Receive News & Ratings for Vertex Pharmaceuticals Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals Incorporated and related companies with MarketBeat.com's FREE daily email newsletter.